Cost-effectiveness of minimally invasive partial nephrectomy and percutaneous cryoablation for cT1a renal cell carcinoma

[1]  Yuhong Yuan,et al.  Ablative therapies versus partial nephrectomy for small renal masses - A systematic review and meta-analysis. , 2021, International journal of surgery.

[2]  Sam S. Chang,et al.  Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II , 2021, The Journal of urology.

[3]  Sam S. Chang,et al.  Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I , 2021, The Journal of urology.

[4]  P. Salvalaggio,et al.  Percutaneous Cryoablation versus Robot-Assisted Partial Nephrectomy of Renal T1A Tumors: a Single-Center Retrospective Cost-Effectiveness Analysis , 2021, CardioVascular and Interventional Radiology.

[5]  C. Georgiades,et al.  Percutaneous Cryoablation for Stage 1 Renal Cell Carcinoma: Outcomes from a 10-year Prospective Study and Comparison with Matched Cohorts from the National Cancer Database. , 2020, Radiology.

[6]  G. Gueglio,et al.  Renal fossa recurrence after radical nephrectomy: Current management, and oncological outcomes. , 2019, Urologic oncology.

[7]  J. Cheville,et al.  Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. , 2019, European urology.

[8]  Yu Shen,et al.  Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II—An Updated Analysis of SEER-Medicare Data , 2019, PharmacoEconomics.

[9]  P. Pierorazio,et al.  Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States. , 2019, European urology oncology.

[10]  P. Slattum,et al.  Economic burden of renal cell carcinoma among older adults in the targeted therapy era. , 2019, Urologic oncology.

[11]  Lorenzo Marconi,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.

[12]  Y. Bao,et al.  Partial nephrectomy vs cryoablation for T1a renal cell carcinoma: A comparison of survival benefit stratified by tumour size. , 2019, Cancer epidemiology.

[13]  A. Masson-Lecomte,et al.  Peri‐operative and local control outcomes of robot‐assisted partial nephrectomy vs percutaneous cryoablation for renal masses: comparison after matching on radiological stage and renal score , 2018, BJU international.

[14]  G. Rücker,et al.  Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis , 2018, European Radiology.

[15]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[16]  R. Mehrazin,et al.  Imaging Protocols for Active Surveillance in Renal Cell Carcinoma , 2018, Current Urology Reports.

[17]  Hyun S Kim,et al.  Ablation versus Resection for Stage 1A Renal Cell Carcinoma: National Variation in Clinical Management and Selected Outcomes. , 2018, Radiology.

[18]  J. Ludwig,et al.  Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked Population Study. , 2018, Radiology.

[19]  J. Skinner,et al.  Regional Variation of Computed Tomographic Imaging in the United States and the Risk of Nephrectomy , 2017, JAMA internal medicine.

[20]  L. Kiemeney,et al.  Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma , 2017, Quality of Life Research.

[21]  Chad A. LaGrange,et al.  Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  William W Mayo-Smith,et al.  Renal Cell Carcinoma: Comparison of RENAL Nephrometry and PADUA Scores with Maximum Tumor Diameter for Prediction of Local Recurrence after Thermal Ablation. , 2017, Radiology.

[23]  D. Laheru,et al.  Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2017, Journal of oncology practice.

[24]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[25]  Nofisat Ismaila,et al.  Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2017, Journal of Oncology Practice.

[26]  Ya-Chen Tina Shih,et al.  Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. , 2015, Clinical genitourinary cancer.

[27]  J. Cheville,et al.  Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. , 2015, European urology.

[28]  J. Cheville,et al.  Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  David C. Miller,et al.  Long-term renal functional outcomes of minimally invasive partial nephrectomy for renal cell carcinoma. , 2014, Urologic oncology.

[30]  Joshua T. Cohen,et al.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.

[31]  R. Thompson,et al.  Predicting renal cryoablation complications: new risk score based on tumor size and location and patient history. , 2014, Radiology.

[32]  S. Bhayani,et al.  Renal cryoablation versus robot-assisted partial nephrectomy: Washington University long-term experience. , 2013, Journal of endourology.

[33]  L. Garrison,et al.  Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[34]  S. Lipsitz,et al.  Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. , 2011, Urology.

[35]  J. Cadeddu,et al.  Cost comparison of robotic, laparoscopic, and open partial nephrectomy. , 2011, Journal of endourology.

[36]  Steven L. Chang,et al.  Cost-effectiveness analysis of nephron sparing options for the management of small renal masses. , 2010, The Journal of urology.

[37]  M. Cooperberg,et al.  Renal cell cancer stage migration , 2008, Cancer.

[38]  G Scott Gazelle,et al.  Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis. , 2008, Radiology.

[39]  I. Gill,et al.  The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. , 2006, The Journal of urology.

[40]  Stephanie Daignault,et al.  Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect , 2006 .

[41]  Andrew J Vickers,et al.  Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. , 2006, The Lancet. Oncology.

[42]  Steven L. Chang,et al.  Adoption of Robot-Assisted Partial Nephrectomies: A Population-Based Analysis of U.S. Surgeons from 2004 to 2013. , 2017, Journal of endourology.

[43]  H. Korman,et al.  Percutaneous Cryoablation vs Partial Nephrectomy: Cost Comparison of T1a Tumors. , 2016, Journal of endourology.

[44]  Mba Sasha N. Bhan MD,et al.  Active Surveillance, Radiofrequency Ablation, or Cryoablation for the Nonsurgical Management of a Small Renal Mass: A Cost-Utility Analysis , 2013, Annals of Surgical Oncology.